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Objectives: Information on the occurrence and frequency of pulmonary involvement in
patients with ulcerative colitis (UC) is inconsistent. Some authors reported pulmonary
impairment with UC by standard pulmonary function tests (PFTs) and documented a
reduced diffusing capacity for carbon monoxide (DLCO) especially in patients with active
disease, whereas others could not detect differences in routine PFTs between UC patients
and controls.
Aim: The aim of this prospective study was to determine the frequency and type of
pulmonary dysfunction in patients with UC with respect to disease activity. Furthermore,
to evaluate the influence of smoking, nutritional status, sputum cytology and
sulphasalazine therapy on PFT parameters.
Patients and methods: Twenty-six patients with UC (20 with active disease, 6 inactive)
and 16 age and sex matched healthy controls were investigated with respect to the
following pulmonary function tests, forced vital capacity (FVC), forced expiratory volume
in the 1 s (FEV1%) and their ratio (FEV1/FVC) and forced expiratory flow 25–75%
(FEF25–75%) as well as oxygen saturation. For UC patients, colonoscopy and biopsy were
done. Disease activity was assessed by Truelove index for UC. Induced sputum was sampled
for cytology. Smoking habit, body mass index (BMI) and medications were recorded.
Results: Fifteen out of 26 patients with UC (57.6%) exhibited at least one pathological
pulmonary function test (o80% of predicted value). Small airway obstruction was reported
in the 15 patients, restrictive dysfunction in 30.7% and obstructive dysfunction in 11.5%.
The impairment of PFTs was significant and more pronounced in patients with active
disease, FVC (14% of predicted), FEV1 (9% of predicted) and FEF25–75% (32% of
predicted), Po0.01, 0.05 and 0.01, respectively. There was no significant influence of
smoking and medications on PFTs.Elsevier Ltd. All rights reserved.
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healthy controls. The impairment in active disease exceeded that during the remission.
Early recognition is important, as they can be strikingly steroid responsive.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) are
associated with a variety of systemic manifestations invol-
ving the respiratory system. Many authors have previously
shown that subjects with unexplained cough1–3 and non-
smoking subjects with fixed airflow obstruction4 have a high
prevalence of organ-specific autoimmune disease and a high
prevalence of organ-specific auto antibodies. Subjects with
inflammatory bowel disease report common respiratory
symptoms more often than healthy controls.5 They have
suggested that the increased respiratory symptoms are due
to airway inflammation as a result of aberrant homing of
inflammatory cells to the lungs from the primary site of
chronic inflammation.1,2,4
The presence of sub clinical disease in patients with
minimal respiratory symptoms was suggested and the
pulmonary function abnormalities have revealed inconsis-
tent results. Whereas some authors could not detect
differences in routine pulmonary function test between
IBD patients and controls,3,6,7 others, documented changes
including a decrease in gas transfer factor,8,9 an elevated
functional residual capacity (FRC) and raised residual
volume (RV) during periods of active bowel disease,10,11
decrease in maximal mid expiratory flow rate12 and an
increased frequency of bronchial hyperresponsiveness.12
Furthermore, alveolar lymphocytosis was evident in bronch-
oalveolar lavage fluid from CD patients without respiratory
symptoms.13
The pulmonary impairment in IBD patients may be related
to disease activity.14,15 Also, side effects of treatments may
contribute to pulmonary dysfunction in IBD patients.16
Hypersensitivity pneumonitis is rare, but has been reported
in some cases for sulfasalazine and mesalazine.17,18
The aim of this prospective study was to determine the
frequency and type of pulmonary dysfunction in patients
with UC with respect to disease activity. Furthermore, the
implication of smoking, nutritional status, sputum cytology
and sulphasalazine therapy on pulmonary function will be
discussed.Subjects and methods
The study was conducted in Tropical Medicine and Gastro-
enterology Departments and Chest Department, Assiut
University Hospital, Egypt. Twenty-six patients with UC
were enrolled in this prospective study. Age and sex
matched normal controls (16 subjects) were recruited from
healthy volunteers living in the same neighborhood.
Patients with UC were diagnosed by thorough history, full
clinical examination. Pulmonary symptoms and signs were
recorded in their entry sheets. Laboratory investigations
including complete blood count (CBC), erythrocyte sedi-mentation rate (ESR) and liver function tests were done.
Abdominal ultra-sonography, colonoscopy and colonic biopsy
and plain X-ray chest were performed. Smoking habits and
medications were documented in every patient.
UC disease activity
The activity of ulcerative colitis was assessed using the
Truelove score.19 This score include stool frequency, fever,
the occurrence of blood in stool and, laboratory findings, as
hemoglobin levels (HB) and erythrocyte sedimentation rate
(ESR). Patients with Truelove indices of mild were consid-
ered to be in remission and patients with indices moderate
and severe had active disease.
Pulmonary function tests, O2 saturation and 6-min
walking test
Pulmonary function testing were performed utilizing Sensor
Medics Corporation Spirometer (Model CA92687, SN 54065,
Osaka, Japan), to measure the predicted forced vital
capacity (FVC%), the predicted forced expiratory volume
in the 1 s (FEV1%) and their ratio (FEV1/FVC) as well as
forced expiratory flow 25–75% (FEF25–75%). Each measure-
ment was repeated at least three times and the highest
acceptable measurement was compared with normal pre-
dicted value. Oxygen saturation was measured using radio-
meter acid–base analyzer ABL 30. Unfortunately, the
diffusing capacity for carbon monoxide (DLCO) was not
measured as it is not available in our center. Walking
distance after 6min walking test was calculated to indicate
the presence and degree of dyspnea in patients and
controls.
Sputum cytology
For sputum induction, sputum was induced with 3%, 4% and
5% saline inhaled in sequence for 5min via an ultrasonic
nebulizer (Medix, Harlow, UK). After each inhalation
patients expectorated into a sterile pot. Sputum free of
salivary contamination was selected and was mixed with
four times its volume of 0.1% dithiothreitol. From the
induced sputum sample, a differential cell count was
obtained from a cytospin preparation stained with Roma-
nowski’s stain, and a total cell count was determined using a
haemocytometer. Cell counting was performed by an
experienced observer blind to the subject’s clinical char-
acteristics.
Exclusion criteria
Reasons for exclusion from this study were abnormal X- ray
chest, signs of infectious bronchitis or pneumonia, and lack
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patients with history of associated chronic diseases (cardiac,
renal, hepatic disease, diabetes or hypertension), metho-
trexate or steroid therapy were excluded.
Statistical analysis
All statistical analyses were performed using the statistical
package SPSS 10.0 for windows (SPSS, Chicago, IL). Data
were tested for normal distribution, expressed as mean7SD.
Analysis of variance by Mann–Whitney test was used to
compare means, and Spearman’s r correlation was used
after simple regression to calculate correlation coefficients.
P values o0.05 were considered to be statistically
significant.
Ethical considerations
Informed consent was obtained from all patients and control
subjects, and the study was approved by the ethical
committee of the Faculty of Medicine, Assiut University
Hospital, Egypt.
Results
Twenty-six patients, 17 males and 9 females (65%/35%) as
well as 16 healthy controls, with mean age 39.574 and
34.773 years old, respectively, were recruited in the study.
The demographic and clinical data of the studied individuals
are summarized in Table 1.
Frequency of respiratory symptoms
Dyspnea on excursion (breathlessness) was the commonest
presenting symptom in patients with all patterns of disease
(40% in patients with active UC, 35% in patients with inactive
UC vs. none of controls, Po0.001 in both). Dry cough wasTable 1 Demographic and clinical data of the studied groups.
Variable Active UC
Male/female 14/6
Smokers 0
Age, years (mean7SD) range 38.273
16–45
Treatment 0
Duration of the disease, months (mean7SD) (range) 2.3+0.5
1–3
Truelove index Moderate
BMI (kg/m2) (mean7SD)
Range 17.273
15.2–23.3
Walking distance, meters (6 MWT) 145.973
BMI ¼ body mass index, 6 MWT ¼ 6-min walking test, UC ¼ ulcera
Comparison between active ulcerative colitis patients and contro
yComparison between active ulcerative colitis patients and inactiv
parametric means.recorded in 25% of patients with active UC and in 15% of
patients with inactive disease (Po0.01 and 0.05 vs.
controls). Sputum production was recorded in 20% of
patients with active UC, but none of patients with inactive
disease had sputum (Po0.01 vs. inactive UC and controls).
None of the patients had history of chest wheeze,
heamoptysis or chest pain. The walking distance was
significantly lower in patients with active disease vs.
inactive cases and controls (145.9732.8 vs. 166.4728.2
and 487.2729.5m, respectively (Po0.01 and 0.000). How-
ever, no significant difference in O2 saturation was recorded
in active UC (95797.8%), inactive UC (94.8798.1%)
compared to controls (97.2798.7%).
Pulmonary function tests in UC patients versus
controls
Fifteen out of 26 patients (57.6%) exhibited at least one
pathological pulmonary function test (o 80% of predicted
value). Small airway obstruction (as evidenced by dimin-
ished FEF 25–75%) was reported in the 15 patients (57.6%),
restrictive dysfunction in 8 patients (30.7%) and obstructive
dysfunction in 3 patients (11.5%). The mean values of FVC,
FEV1, FEV1/FVC% and FEF25–75% as well as the percentage
of predicted normal were recorded in patients and controls
in Table 2.
The impairment in PFTs was significant and more
pronounced in patients with active UC versus controls, FVC
(14% of predicted), FEV1 (8.5% of predicted), and
FEF25–75% (32% of predicted), Po0.01, 0.05 and 0.01,
respectively. Also, the changes in pulmonary functions were
significantly evident in patients with active UC vs. patients
with inactive UC (Table 2).
Sputum cytology results
In Table 3, induced sputum cytology results demonstrated
significant increase in absolute and differential lymphocytic(n ¼ 20) Inactive UC (6) Controls (n ¼ 16) P-value
3/3 10/6 NS
3 0 NS
39.877 34.773 NS
16–45 22–38
6 0 —
6.371.7 0 —
1–36
, severe Mild 0 —
18.4+2.8 23.173 0.001
16.2–20.4 18–26.1
2.8 166.4728.2y 487.2729.5 0.000
0.01y
tive colitis.
ls.
e UC patients. Mann–Whitney test was used to compare the non-
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Table 2 Changes in pulmonary function parameters in patients with active, inactive UC and controls (mean7SD).
Variable Active UC (20) Inactive UC (6) Controls (16)
FVC, liters (%) 2.7570.66 (66) 3.8070.51(88.7)y 3.9371.03 (85.3)
FEV1, liters (%) 2.0370.43
 (71.5) 2.9970.48 (83.4)$ 3.0670.95 (85.0)
FEV1/FVC% 82.9 83.1 85.0
FEF25–75%, Liters/s (%) 1.6470.21 (58.4) 1.9770.19z (64.2)$ 2.4470.86 (91)$
Data are expressed as mean +SD and percentage of predicted (%), Po0.05 was considered significant (Mann–Whitney test).
Comparison between active UC and controls.
yComparison between active UC and inactive.
zComparison between inactive UC and controls.
Table 3 Induced sputum cell counts and differential counts in the studied groups.
Variable Active UC (20 patients) Inactive UC (6 patients) Controls (16 subjects)
Absolute cell count (cell/HPF)
Neutrophils 7.270.9 6.170.4 7.471.5
Eosinophils 5.374.1 3.270.2y,z 0.470.1
Lymphocytes 13.575.3 8.074.5y,z 4.672.1
Macrophages 10.572.6 10.370.8y 29.172.7
Epithelial cell 2.170.4 2.470.7 0.570.2
Differential cell counts (%)
Neutrophils 18.6 14.1 17.6
Eosinophils 13.7 12.3y 0.09
Lymphocytes 34.9 30.7y 10.9
Macrophages 27.2 39.6y,z 69.4
Epithelial cell 5.4 9.2y,z 0.1
HPF ¼ high power field, data were expressed as mean7SD or %.
* # $ ¼ Po 0.05 (Mann–Whitney test).
Comparison between active UC and controls.
yComparison between inactive UC and controls.
zComparison between active UC and inactive.
A.A.R. Mohamed-Hussein et al.980and eosinophilic counts compared to controls (Po 0.01 and
0.05). The induced sputum lymphocytosis and eosinophilia
were more pronounced in active UC compared to inactive
UC.Correlation between pulmonary function
parameters with disease activity, BMI, smoking,
treatment, and sputum lymphocytosis and
eosinophilia
We noticed significant negative correlation between UC
activity, sputum lymphocytosis, eosinophilia and pulmonary
function parameters (FVC%, FEV1% and FEF25–75%). Also,
there was significant positive correlation between BMI and
PFT parameters. No, correlation between sulphasalazine
therapy and PFTs parameters or between sulphasalazine and
induced sputum lymphocytosis. The number of smokers in
this study was a limitation factor in doing proper correlation
(smokers were only 3 subjects). So, it was unlikely that
smoking contributed to the pulmonary disease in the studied
group (Table 4).Discussion
UC is a chronic idiopathic inflammatory bowel disease with
remissions and exacerbations. The prevalence of UC in Egypt
is increasing, and in one study the frequency of new cases of
UC was 25 cases in year 1997 increased to 52 cases in year
1999.20
The true prevalence of the association between lung
disease and IBD remains unknown, and although it was only
found in three of 1400 cases in one study,21 various factors
suggest that this figure is an underestimate of the true
prevalence of the association. Firstly, clinicians may not
consider this association as patients often present with
pulmonary symptoms years after the bowel disease change
and after being discharged from gastrointestinal follow-up.4
Asymptomatic patients can have abnormal pulmonary
function8,12 or alveolar lymphocytosis13 and therefore may
not present to a respiratory physician.
We investigated the frequency and type of abnormal
pulmonary function in patients with ulcerative colitis in
comparison with normal age and sex-matched healthy
controls. Also, the influences of disease activity, sulphasalazine
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Table 4 Correlation between pulmonary function parameters with disease activity, BMI, treatment, and sputum
lymphocytosis and sputum eosinophilia.
FVC% FEV1% Ratio FEF25–75% Sputum lymphocytosis
Disease activity r ¼ 0.327 r ¼ 0.470z NS r ¼ -0.670z r ¼ 0.552z
BMI r ¼ 0.255 r ¼ 0.343z NS r ¼ 0.430z —
Sulphasalazine therapy NS NS NS NS NS
Sputum lymphocytosis r ¼ 0.330z r ¼ - 0.361z NS r ¼ 0.441z —
Sputum eosinophilia r ¼ 0.462z r ¼ 0.287 NS r ¼ 0.694z r ¼ 0.459z
Spearman’s r correlation for non-parametric variables.
Correlation is significant at the o0.05 level (2-tailed).
zCorrelation is significant at the o0.01 level (2-tailed).
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were analyzed.
In this study, patients with active UC had respiratory
symptoms in the form of dyspnea on exersion (40% vs. 33.3%
in patients with active vs. inactive UC). Dry cough was
recorded in 20%, 16% of patients with active and inactive
UC. These results are similar to the findings of Birring et al.,
who recorded dyspnea and cough in 36% and 24% of patients
with treated UC and Crohn’ disease.3 Also, in the present
study it was found that the sputum production was recorded
in 20% of patients with active UC and none of the patients
with inactive disease. Similarly, copious sputum production
was reported as a characteristic feature of the bronchiec-
tasis associated with UC in some studies.12,22
We detected abnormal results in pulmonary function tests
(defined as o80% of predicted value) in a surprisingly large
proportion of UC patients (57.6%). The most common
abnormality was the decrease in FEF25–75%. Similar results
of decrease in maximal mid expiratory flow rate were found
in about 22% of cases with UC.11,23 Furthermore, we
recorded significant reduction of FVC, FEV1 in patients with
active UC compared to inactive group and controls, while
the ratio of FEV1/FVC% was not significantly different. These
results are consistent with earlier results suggesting a
restrictive pattern of lung function impairment in UC
patients (this was recorded in 30.7% of our cases).7,11,15
The diffusing capacity of carbon monoxide (DLCO) seems to
be a very important limitation in our study. Earlier studies
measuring DLCO in inflammatory bowel diseases, did not find
an influence of the disease,13,23 but recent studies found
DLCO to be significantly diminished specially in active
disease.14,15 Early endothelial involvement is common
inflammatory bowel disease and may affect lung endothelial
as well.24
The influence of disease activity was studied. We found
that the mean values as well as the percentage of predicted
FVC, FEV1, FEF25–75% were significantly lower in patients
with active UC vs. inactive disease and with significant
negative correlation between these indices of PFTs and
disease activity. Herrlinger et al. recorded similar results in
45% of UC patients with active disease and added that
alterations in PFTs are more frequent in active cases and
persist during remission.15
It is important to consider whether therapy with
sulphasalazine or mesalazine may have been responsible
for the pulmonary changes. The most common abnormalitydescribed in association with sulphasalazine therapy is
upper lobe peripheral opacities, although lower lobe
opacities, eosinophilic pneumonia, interstitial pneumonitis,
BOOP and cavitating nodules have also been reported.16–18
Six of our patients were taking sulfasalazine for more than 6
months. There was no radiologic evidence of similar
involvements. Furthermore, none of these patients had
peripheral blood eosinophilia, which is usually present in
lung disease caused by sulphasalazine. Moreover, there was
no correlation between sulphasalazine use and the changes
recorded neither in PFTs indices nor with sputum lympho-
cytosis. These features make it unlikely that the drug
contributed to the pulmonary abnormalities seen in the
patients. However, we noticed induced sputum eosinophilia
(absolute and differential) in this group which may be an
early indication that longer duration of this group of drugs
may affect the lung; therefore, monitoring the side effect of
this drug should be done on larger scale of patients to
further clarify this point.
The nutritional status has been shown to have significant
influence on the overall pulmonary function in patients with
inflammatory bowel disease. Christie and Hill demonstrated
a 35% loss of body protein stores and associated –40%
physiological impairment (FEV1, FVC and maximal voluntary
ventilation, MVV) in patients with acute exacerbations of CD
compared to controls. There was significant immediate and
delayed improvement of these parameters after 2 weeks of
nutritional supplementation and further improvement on
restoration of body proteins during convalescence.25 Simi-
larly, we examined the body mass index (BMI, kg/m2) as an
index of the nutritional status of both groups with UC and
controls and we found significant positive correlation
between BMI and pulmonary function results.
Lastly, the mechanism of pulmonary involvement in
autoimmune diseases is unclear. One proposed mechanism
for explaining this association is the common embryological
derivation of the lungs and gastrointestinal tract from the
primitive foregut, and the similarity in the immune systems
in the pulmonary and intestinal mucosa.4 Other theory
suggested that lymphocytes sensitized from the GIT may
induce inflammation on the mucosal surfaces of other
organs. In CD, alveolar lymphocytosis has been reported
among patients free of clinical symptoms.13,26 A recent
study investigating induced sputum in CD patients found
the CD4/CD8 quotient to be abnormally high in patients
with active disease relative to patients in remission.27
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recorded in all UC patients with pulmonary dysfunction in
the present work, and the induced sputum lymphocytosis
was significantly correlated with decrease in FVC, FEV1 and
FEF25–75%.
A large proportion of the patients had pulmonary disease
that was responsive to steroids either orally as in the case of
alveolar disease or inhaled or orally or both, in airway
disease. These observations suggest that the pulmonary
disease in CD and UC has an inflammatory basis.
In summary, taken together, subclinical pulmonary dys-
function is frequent in UC and dependent on disease activity.
Some alterations were sub-clinical and some of the patient
showed troublesome pulmonary symptoms. Pathophysiolo-
gical mechanisms and clinical relevance are to be further
clarified. Early detection is important as both the alveolar
and airway disease often respond well to steroid treatment.
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